Bharat Ramratnam

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10960947/publications.pdf Version: 2024-02-01



<u> ΒΗΛΡΛΤ ΡΛΜΡΛΤΝΛΜ</u>

#	Article	IF	CITATIONS
1	Neurotoxicity of HIV-1 Tat is attributed to its penetrating property. Scientific Reports, 2020, 10, 14002.	3.3	12
2	Impact of exosomal HIV-1 Tat expression on the human cellular proteome. Oncotarget, 2019, 10, 5632-5644.	1.8	1
3	Exosomal Tat protein activates latent HIV-1 in primary, resting CD4+ T lymphocytes. JCl Insight, 2018, 3, .	5.0	37
4	SILAC Based Proteomic Characterization of Exosomes from HIV-1 Infected Cells. Journal of Visualized Experiments, 2017, , .	0.3	4
5	Lactobacillus-derived extracellular vesicles enhance host immune responses against vancomycin-resistant enterococci. BMC Microbiology, 2017, 17, 66.	3.3	108
6	The impact of pregnancy on anti-HIV activity of cervicovaginal secretions. American Journal of Obstetrics and Gynecology, 2016, 215, 748.e1-748.e12.	1.3	12
7	Targeted proteomics: Current status and future perspectives for quantification of food allergens. Journal of Proteomics, 2016, 143, 15-23.	2.4	55
8	Proteomic Characterization of Exosomes from HIV-1-Infected Cells. Methods in Molecular Biology, 2016, 1354, 311-326.	0.9	7
9	Glycogen synthase kinase 3 beta inhibits microRNA-183-96-182 cluster via the β-Catenin/TCF/LEF-1 pathway in gastric cancer cells. Nucleic Acids Research, 2014, 42, 2988-2998.	14.5	79
10	Acetylation of Drosha on the N-Terminus Inhibits Its Degradation by Ubiquitination. PLoS ONE, 2013, 8, e72503.	2.5	48
11	Stable cell fate changes in marrow cells induced by lungâ€derived microvesicles. Journal of Extracellular Vesicles, 2012, 1, .	12.2	40
12	A new stem cell biology: the continuum and microvesicles. Transactions of the American Clinical and Climatological Association, 2012, 123, 152-66; discussion 166.	0.5	11
13	Marrow cell genetic phenotype change induced by human lung cancer cells. Experimental Hematology, 2011, 39, 1072-1080.	0.4	32
14	The Evi1, microRNA-143, K-Ras axis in colon cancer. FEBS Letters, 2011, 585, 693-699.	2.8	27
15	Glycogen Synthase Kinase 3 Beta (GSK3β) Phosphorylates the RNAase III Enzyme Drosha at S300 and S302. PLoS ONE, 2011, 6, e20391.	2.5	58
16	Microvesicle entry into marrow cells mediates tissue-specific changes in mRNA by direct delivery of mRNA and induction of transcription. Experimental Hematology, 2010, 38, 233-245.	0.4	186
17	Atypical transcription of microRNA gene fragments. Nucleic Acids Research, 2010, 38, 2775-2787.	14.5	12
18	Phosphorylation of the RNase III enzyme Drosha at Serine300 or Serine302 is required for its nuclear localization. Nucleic Acids Research, 2010, 38, 6610-6619.	14.5	72

BHARAT RAMRATNAM

#	Article	IF	CITATIONS
19	MicroRNA 125a and its regulation of the p53 tumor suppressor gene. FEBS Letters, 2009, 583, 3725-3730.	2.8	87
20	Acetylation-Dependent Signal Transduction for Type I Interferon Receptor. Cell, 2007, 131, 93-105.	28.9	175
21	Overcoming HIV-1 resistance to RNA interference. Frontiers in Bioscience - Landmark, 2007, 12, 3104.	3.0	13
22	RNAi tackles a sexually transmitted disease. Nature Biotechnology, 2006, 24, 48-49.	17.5	8
23	Engineering Mucosal RNA Interference in Vivo. Molecular Therapy, 2006, 14, 336-342.	8.2	91
24	Enhanced gene silencing of HIV-1 specific siRNA using microRNA designed hairpins. Nucleic Acids Research, 2004, 32, 1154-1158.	14.5	202
25	Intensification of Antiretroviral Therapy Accelerates the Decay of the HIV-1 Latent Reservoir and Decreases, But Does Not Eliminate, Ongoing Virus Replication. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 35, 33-37.	2.1	103
26	Efficient Gene Transfer of HIV-1-Specific Short Hairpin RNA into Human Lymphocytic Cells Using Recombinant Adeno-associated Virus Vectors. Molecular Therapy, 2004, 9, 396-402.	8.2	48
27	Human Immunodeficiency Virus Type 1 Escape from RNA Interference. Journal of Virology, 2003, 77, 11531-11535.	3.4	390
28	Promoter choice affects the potency of HIV-1 specific RNA interference. Nucleic Acids Research, 2003, 31, 5033-5038.	14.5	93
29	Nucleotide sequence homology requirements of HIV-1-specific short hairpin RNA. Nucleic Acids Research, 2003, 31, 6444-6449.	14.5	62
30	Residual Viral Replication during Antiretroviral Therapy Boosts Human Immunodeficiency Virus Type 1-Specific CD8 + T-Cell Responses in Subjects Treated Early after Infection. Journal of Virology, 2002, 76, 411-415.	3.4	25
31	Discontinuation of Antiretroviral Therapy Commenced Early during the Course of Human Immunodeficiency Virus Type 1 Infection, with or without Adjunctive Vaccination. Journal of Infectious Diseases, 2002, 186, 634-643.	4.0	129
32	The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nature Medicine, 2000, 6, 82-85.	30.7	435
33	Genetic characterization of rebounding HIV-1 after cessation of highly active antiretroviral therapy. Journal of Clinical Investigation, 2000, 106, 839-845.	8.2	162
34	Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis. Lancet, The, 1999, 354, 1782-1785.	13.7	458
35	Quantifying Residual HIV-1 Replication in Patients Receiving Combination Antiretroviral Therapy. New England Journal of Medicine, 1999, 340, 1605-1613.	27.0	782
36	A recombinant vaccinia virus based ELISPOT assay detects high frequencies of Pol-specific CD8 T cells in HIV-1-positive individuals. Aids, 1999, 13, 767-777.	2.2	206

#	Article	IF	CITATIONS
37	Former Prisoners' Views on Mandatory HIV Testing During Incarceration. Journal of Correctional Health Care, 1997, 4, 155-164.	0.5	9
38	A study of cross-coverage calls. Journal of General Internal Medicine, 1996, 11, 189-189.	2.6	1
39	Management of persistent B19 parvovirus infection in AIDS. British Journal of Haematology, 1995, 91, 90-92.	2.5	24